1. Indonesia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
PT Tempo Scan Pacific Tbk

PT Tempo Scan Pacific Tbk

PEXXF
PT Tempo Scan Pacific TbkUS flagOther OTC
0.09
USD
- -
- -
463.12MMarket Cap
PT Tempo Scan Pacific Tbk
PEXXF
(Other OTC)

Recent

price

0.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2,436.48
- -
- -
2,908.25
3,027.59
- -
2,996.53
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
175
- -
- -
261
321
- -
295.48
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-99.48
- -
- -
-72.41
-56.47
- -
-96.1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
40.76
- -
- -
128.16
88.04
- -
22.29
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1,250.8
- -
- -
1,610.27
1,829.94
- -
1,890.98
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1,416.62
- -
- -
1,787.9
2,028.99
- -
2,099.82
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4,502
- -
- -
4,511
4,510
- -
4,497
Basic Weighted Avg Shares
5,134,242
5,780,664
6,630,810
6,854,889
7,512,115
8,181,482
9,138,239
9,565,462
10,088,119
10,993,842
10,968,402
11,234,443
12,254,369
13,119,785
13,654,571
14,005,028
13,476,263
Sales/Revenue/Turnover
10.9
11.47
11.22
11.08
9
8.49
7.59
6.65
6.99
7.29
9.84
9.87
5.99
8.27
13.27
12.16
11.27
Operating Margin (%)
- -
- -
76,795
74,529
88,971
116,328
125,308
122,000
128,989
137,707
178,400
189,721
191,698
189,524
305,148
196,829
300,580
Depreciation Expense
488,889
566,048
627,950
634,623
580,870
521,959
536,274
543,804
512,029
554,263
787,803
823,768
1,001,628
1,177,432
1,447,725
1,406,764
1,328,870
Net Income, GAAP
21.4
20.77
21.81
23.06
20.66
25.16
24.13
25.1
25.74
25.25
21.61
20.08
21.98
22.01
20
18.71
15.4
Effective Tax Rate (%)
9.52
9.79
9.47
9.26
7.73
6.38
5.87
5.69
5.08
5.04
7.18
7.33
8.17
8.97
10.6
10.04
9.86
Profit Margin (%)
1,838,960
2,075,573
2,296,644
2,643,650
2,477,369
2,608,435
2,731,671
3,046,742
3,091,587
3,479,030
3,933,073
4,343,725
4,590,003
4,774,667
5,940,682
6,170,678
6,125,038
Working Capital
3,635
2,398
2,119
1,772
4,965
4,081
20,134
15,155
- -
206,320
338,835
473,235
372,008
70,732
59,019
62,232
55,860
LT Debt
2,644,733
3,045,936
3,353,156
3,835,547
4,082,128
4,337,141
4,635,273
5,082,008
5,432,848
5,791,036
6,377,236
6,875,304
7,550,757
8,065,637
9,150,827
9,660,126
9,443,494
Total Equity
16.48
17.41
17.27
15.46
12.96
11.94
11.26
9.26
9.23
9.67
12.34
11.72
6.72
9.16
14.86
13.14
12.64
Return on Invested Capital (%)
19.9
20.13
20.42
18.9
16.15
13.62
12.86
11.77
9.69
9.61
12.31
11.5
12.76
13.47
15.33
13.97
13.74
Return on Capital (%)
21.3
21.98
21.57
19.9
16.93
14.21
13.55
12.79
11.23
11.32
14.72
14.05
15.57
16.78
18.66
16.55
16.35
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
799,833
1,112,513
1,027,688
LT Borrowings
- -
- -
- -
LT Finance Leases
59,019
50,832
55,860
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,510
4,510
4,510
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
8,789,500
9,479,723
8,917,241
Cash, Cash Equivalents & STI
4,584,564
4,808,824
4,434,279
Accounts Receivable, Net
1,502,989
1,571,394
1,464,606
Inventories
2,191,259
2,393,963
2,327,092
Total Current Liabilities
2,848,819
3,128,228
2,792,203
Payables & Accruals
- -
- -
- -
ST Debt
799,833
1,112,513
1,027,688
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.36%
8.69%
5.57%
Free Cash Flow
10.24%
5.52%
54.84%
Net Income, GAAP
11.25%
12.77%
-2.83%
Sales/Revenue/Turnover
5.58%
5.04%
2.57%
Total Cash Common Dividend
21.91%
46.2%
104.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,441,768
3,335,251
3,373,355
3,504,196
13,654,571
2025
3,275,227
3,323,485
3,871,148
- -
14,005,028
2026
3,413,260
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
90
- -
- -
- -
321
2025
91
- -
- -
- -
- -
2026
78
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
88.04
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Prince Pharmaceutical Co., Ltd. (6935.TWO)
Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ)
Elite Pharmaceuticals, Inc. (ELTP)
Zydus Lifesciences Limited (CADILAHC.NS)
NATCO Pharma Limited (NATCOPHARM.BO)
Ilyang Pharmaceutical Co.,Ltd (007575.KS)
Business
PT Tempo Scan Pacific Tbk engages in the manufacturing, marketing, and distribution of pharmaceuticals, consumer products, cosmetics, and related services primarily in Indonesia and select international markets. The company operates through three main segments: Pharmaceuticals, offering prescription drugs, over-the-counter medications including analgesics, cough and cold remedies, anti-rheumatism products, vitamins, minerals, supplements, herbal solutions, beverages, and nutritional items; Consumer Products and Cosmetics, producing and selling soaps, toothpastes, toothbrushes, fragrances, facial care products, hand and body lotions, floor cleaners, baby products, powder milk, food and beverages, plastic packaging, and household items under brands such as Bodrex, Oskadon, Neo Rheumacyl, Bodrexin, Vidoran, Hemaviton, Neo Hormoviton, Polaris, Vitonal, Marina, Claudia, and Ultima II; and Distribution Services, providing warehousing, procurement, sales, and delivery through approximately 48 branches and 238 sites across Indonesia to pharmaceutical, modern retail, and general trade channels. Founded in 1970 as PT Scanchemie and headquartered at Tempo Scan Tower in Jakarta, Indonesia, the company functions as a subsidiary of PT Bogamulia Nagadi and maintains operations in Thailand since 2007, the Philippines since 2010, and Malaysia since 2012. Recent developments include the inauguration of a new formula milk and growth milk raw material production facility by PT Kian Mulia Manunggal in Cikarang, recognition with the Indonesia Most Excellent Company (IMECO) Award 2025 for employee health and community wellbeing initiatives, a IDR 1.75 trillion credit facility from PT Bank OCBC NISP Tbk in 2022, and ongoing support for nutritional programs and humanitarian aid efforts.